US launch for Xenazine
This article was originally published in Scrip
Ovation Pharmaceuticalshas launched Xenazine (tetrabenazine) in the US, making it the first product for the treatment of chorea in Huntington's disease to be made available there. The product has a wholesale acquisition cost of about $3,000 for a 12mg bottle and $6,000 for 25mg, which gives an annual price of between $30,000 and $50,000 depending on the individual patient's needs, Ovation says. It will be marketed by Ovation's 48-person sales force to specialists in CNS disorders, and the company is offering a financial patient support programme for those in need.
You may also be interested in...
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.
Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.